Background
Methods
Analysis of NSCLC data in cBioportal for Cancer Genomics database
Patients and tissue specimens
Variable | Learning cohort | Validation cohort | ||||||
---|---|---|---|---|---|---|---|---|
Cases | Negative expression (%) | Positive expression (%) |
P-value* | Cases | Negative expression (%) | Positive expression (%) |
P-value* | |
Age(years) | ||||||||
<56a
| 42 | 21(50%) | 21(50%) | 0.068 | 22 | 13(59.1%) | 9(40.9%) | 0.443 |
≥56a
| 51 | 35(68.6%) | 16(31.4%) | 29 | 14(48.3%) | 15(51.7%) | ||
Gender | ||||||||
Male | 61 | 39(63.9%) | 22(36.1%) | 0.312 | 35 | 17(48.6%) | 18(51.4%) | 0.355 |
Female | 32 | 17(53.1) | 15(46.9%) | 16 | 10(62.5) | 6(37.5%) | ||
Smoking Condition | ||||||||
Smoker | 42 | 32(76.2%) | 10(23.8%) | 0.004 | 20 | 16(80%) | 4(20%) | 0.002 |
Nonsmoker | 51 | 24(47.1%) | 27(52.9%) | 31 | 11(35.5%) | 20(64.5%) | ||
WHO grade | ||||||||
G1 | 28 | 18(64.3%) | 10(35.7%) | 0.708 | 16 | 9(56.2%) | 7(43.8%) | 0.843 |
G2 | 37 | 22(62.2%) | 15(37.8%) | 20 | 11(55%) | 9(45%) | ||
G3 | 28 | 16(57.1%) | 12(42.9%) | 15 | 7(46.7%) | 8(53.3%) | ||
Histological Type | ||||||||
Squamous cell carcinoma | 37 | 29(78.4%) | 8(21.6%) | 0.002 | 22 | 16(72.7%) | 6(27.3%) | 0.046 |
Adenocarcinoma | 46 | 25(54.3%) | 21(45.7%) | 23 | 9(39.1%) | 14(60.9%) | ||
Others | 10 | 2(25%) | 8(75%) | 6 | 2(33.3%) | 4(77.7%) | ||
T stage | ||||||||
T1-T2 | 38 | 15(39.5%) | 23(60.5%) | 0.001 | 18 | 4(22.2%) | 14(88.8%) | 0.001 |
T3-T4 | 55 | 41(74.5%) | 14(25.5%) | 33 | 23(69.7%) | 10(30.3%) | ||
N stage | ||||||||
N0 | 26 | 9(34.6%) | 15(57.7%) | 0.005 | 16 | 5(31.2%) | 11(68.8%) | 0.036 |
N1-N3 | 67 | 47(70.1%) | 22(29.9%) | 35 | 22(62.9%) | 13(37.1%) | ||
M stage | ||||||||
M0 | 66 | 45(68.2%) | 21(31.8%) | 0.014 | 35 | 14(40%) | 21(60%) | 0.006 |
M1 | 27 | 11(40.7%) | 16(59.3%) | 16 | 13(81.2%) | 3(18.8%) | ||
TNM stage | ||||||||
I-II | 25 | 6(24%) | 19(76%) | 0.000 | 14 | 4(28.6%) | 10(71.4%) | 0.032 |
III-IV | 68 | 50(73.5%) | 18(26.5%) | 37 | 23(62.2%) | 14(37.8%) |
Immunohistochemistry (IHC)
Immunohistochemistry evaluation
Quantitative real-time polymerase chain reaction (qRT-PCR) analysis
Cell lines and recombinant lentiviral vector construction
MTT proliferation assay
Colony forming assay and Western blot analysis
EdU incorporation
Flow-cytometry analysis and Cell cycle antibody array
Xenograft assay
Statistical analysis
Results
Deletion of PinX1 gene and decreased expression of PinX1 in NSCLC patients
PinX1 associated with NSCLC patients’ clinicopathological features
PinX1 serves as an independent indicator for NSCLC patients’ poor survival
Variable | Learning cohort | Validation cohort | ||||||
---|---|---|---|---|---|---|---|---|
Cases | Mean survival (months) | Media survival (months) |
P-value* | Cases | Mean survival (months) | Media survival (months) |
P-value* | |
Age(years) | ||||||||
<56a
| 42 | 27.6 | 25 | 0.199 | 22 | 26.3 | 21 | 0.899 |
≥56a
| 51 | 31.8 | 29 | 29 | 25.6 | 22 | ||
Gender | ||||||||
Male | 61 | 29.4 | 27 | 0.996 | 35 | 24.2 | 19 | 0.385 |
Female | 32 | 29.7 | 26 | 16 | 29.6 | 22 | ||
Smoking Condition | ||||||||
Smoker | 42 | 22.5 | 18 | 0.000 | 20 | 20.1 | 17 | 0.042 |
Nonsmoker | 51 | 35.4 | 33 | 31 | 29.7 | 27 | ||
WHO grade | ||||||||
G1 | 28 | 28.1 | 21 | 0.942 | 16 | 17.5 | 14 | 0.012 |
G2 | 37 | 30.3 | 27 | 20 | 26.4 | 22 | ||
G3 | 28 | 29.8 | 32 | 15 | 34.2 | 29 | ||
Histological Type | ||||||||
Squamous cell carcinoma | 37 | 26.5 | 21 | 0.293 | 22 | 21.3 | 18 | 0.252 |
Adenocarcinoma | 46 | 29.8 | 27 | 23 | 28.2 | 24 | ||
Others | 10 | 36.5 | 32 | 6 | 35.2 | 27 | ||
T stage | ||||||||
T1-T2 | 38 | 39.1 | 37 | 0.000 | 18 | 31.6 | 31 | 0.009 |
T3-T4 | 55 | 22.4 | 16 | 33 | 23.3 | 19 | ||
N stage | ||||||||
N0 | 26 | 43.4 | 49 | 0.000 | 16 | 35.6 | 27 | 0.011 |
N1-N3 | 67 | 24.1 | 21 | 35 | 21.4 | 18 | ||
M stage | ||||||||
M0 | 66 | 35.6 | 34 | 0.000 | 35 | 30 | 25 | 0.004 |
M1 | 27 | 15 | 12 | 16 | 17 | 15 | ||
TNM stage | ||||||||
I-II | 25 | 38.9 | 38 | 0.003 | 14 | 36.5 | 27 | 0.008 |
III-IV | 68 | 26 | 24 | 37 | 21.8 | 18 | ||
PinX1 expression | ||||||||
Negative | 56 | 24.8 | 21 | 0.008 | 27 | 19.4 | 18 | 0.005 |
Positive | 37 | 36.2 | 34 | 24 | 32.6 | 28 |
Variable | Learning cohort | Validation cohort | ||||
---|---|---|---|---|---|---|
HR | 95% Cl |
P-value | HR | 95% Cl |
P-value | |
PinX1 expression | 0.577 | 0.335-0.991 | 0.046 | 0.441 | 0.191-0.882 | 0.023 |
T stage | 2.061 | 1.222-3.482 | 0.007 | 5.434 | 2.162-13.660 | 0.000 |
N stage | 2.590 | 1.340-5.009 | 0.005 | 2.392 | 1.113-5.141 | 0.000 |
M stage | 4.886 | 2.766-8.630 | 0.000 | 3.485 | 1.777-6.837 | 0.000 |
TNM stage | 2.725 | 1.330-5.584 | 0.006 | 2.743 | 1.331-5.650 | 0.006 |
PinX1 suppresses cell proliferation and clonogenicity of NSCLC cell lines in vitro
PinX1 arrested G1/S phase transition of the cell cycle
PinX1 correlated P15 and cyclinD1 expression in NSCLC cells
PinX1 silencing increases xenograft tumor growth in vivo
PinX1 associated with cell proliferation and cell cycle transition relies on BMP5 in NSCLC cell lines
Correlation between the expression of PinX1 and BMP5 in NSCLC patients
Learning cohort | Validation cohort | |||||||
---|---|---|---|---|---|---|---|---|
Cases | BMP-5 Low expression (%) | BMP-5 High expression (%) |
P-value* | Cases | BMP-5 Low expression (%) | BMP-5 High expression (%) |
P-value* | |
PinX1 Negative expression | 56 | 31(33.3%) | 25(26.9%) |
P = 0.015 (r = 0.252) | 27 | 17(33.3%) | 10(19.6%) |
P = 0.006 (r = 0.381) |
PinX1 Positive expression | 37 | 10(10.8%) | 27(29%) | 24 | 6(11.8%) | 18(35.3%) |